PMC5477132_01
Nivolumab and Bilirubin
40425_2017_252_Fig1_HTML.jpg
PMC5477132_01_40425_2017_252_Fig1_HTML.jpg
Fig1
One week after the first dose of nivolumab both his hepatic encephalopathy and constitutional symptoms started to improve, and after 2 doses, (January 2016) his LFTs were almost back to normal (AST 26 IU/L, ALT 15 IU/L, AP 157 IU/L and TB 1.3 mg/dl) (Fig. 1).
Nivolumab and Liver Function Tests
40425_2017_252_Fig2_HTML.jpg
PMC5477132_01_40425_2017_252_Fig2_HTML.jpg
Fig2
IU/L, ALT 15 IU/L, AP 157 IU/L and TB 1.3 mg/dl) and only mild thrombocytopenia (126.000/mm3) (Fig. 2). Importantly, both HIV-1 viral load and CD4 counts have remain stable on ART (undetectable and 126/uL, respectively), and he has not experience any immune related adverse events (irAEs) after 24 doses of nivolumab on his continued therapy with ART regimen (elvitegravir, cobicistat, emtricitabine and tenofovir.)